Haemonetics (NYSE:HAE) Stock Gets Price Target Bump from BTIG Research

Haemonetics (NYSE:HAE) had its price objective hoisted by BTIG Research from $130.00 to $142.00 in a note issued to investors on Thursday, Marketbeat reports. The brokerage presently has a “buy” rating on the medical instruments supplier’s stock. BTIG Research‘s target price would suggest a potential upside of 18.46% from the company’s previous close.

Several other research firms have also weighed in on HAE. JPMorgan Chase & Co. boosted their price target on Haemonetics from $62.00 to $86.00 and gave the stock a “neutral” rating in a research report on Friday, August 7th. Mizuho boosted their target price on shares of Haemonetics from $95.00 to $140.00 and gave the stock an “outperform” rating in a report on Friday, October 9th. Weiss Ratings upgraded shares of Haemonetics from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, August 11th. Citigroup lifted their price objective on shares of Haemonetics from $79.00 to $92.00 and gave the company a “neutral” rating in a research report on Friday, August 7th. Finally, Wall Street Zen upgraded shares of Haemonetics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, Haemonetics has a consensus rating of “Moderate Buy” and an average target price of $126.38.

Haemonetics Price Performance

Shares of HAE stock traded down $4.24 during trading hours on Thursday, reaching $119.87. 834,665 shares of the company were exchanged, compared to its average volume of 762,819. Haemonetics has a fifty-two week low of $51.00 and a fifty-two week high of $132.00. The stock’s fifty day moving average is $111.48 and its two-hundred day moving average is $80.05. The company has a market cap of $5.45 billion, a price-to-earnings ratio of 53.75, a P/E/G ratio of 2.40 and a beta of 0.63. The company has a debt-to-equity ratio of 1.40, a current ratio of 3.08 and a quick ratio of 1.91.

Haemonetics (NYSE:HAE) last posted its quarterly earnings data on Thursday, November 5th. The medical instruments supplier reported $1.35 earnings per share for the quarter, topping the consensus estimate of $1.29 by $0.06. Haemonetics had a net margin of 7.12% and a return on equity of 27.55%. The firm had revenue of $357.76 million during the quarter, compared to analysts’ expectations of $345.15 million. During the same quarter in the previous year, the company posted $1.27 EPS. Haemonetics’s revenue was up 9.4% on a year-over-year basis. Sell-side analysts forecast that Haemonetics will post 5.29 earnings per share for the current fiscal year.

Institutional Trading of Haemonetics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Brighton Jones LLC acquired a new stake in Haemonetics during the 3rd quarter worth about $264,000. May Hill Capital LLC boosted its holdings in Haemonetics by 12.1% during the third quarter. May Hill Capital LLC now owns 25,093 shares of the medical instruments supplier’s stock worth $2,642,000 after purchasing an additional 2,705 shares during the last quarter. Vise Technologies Inc. purchased a new stake in Haemonetics in the 3rd quarter valued at about $613,000. VIRGINIA RETIREMENT SYSTEMS ET Al grew its holdings in shares of Haemonetics by 178.6% in the third quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 11,700 shares of the medical instruments supplier’s stock valued at $1,232,000 after acquiring an additional 7,500 shares in the last quarter. Finally, VestGen Advisors LLC purchased a new stake in shares of Haemonetics during the third quarter valued at approximately $2,901,000. Institutional investors own 99.67% of the company’s stock.

Key Haemonetics News

Here are the key news stories impacting Haemonetics this week:

• Positive Sentiment: Quarterly results beat expectations: Haemonetics earned $1.35 per share versus estimates of $1.29 and generated $357.8 million in revenue, above the $345.2 million consensus and up 9.4% year over year. Earnings and outlook report
• Positive Sentiment: Raised fiscal 2027 outlook: The company increased its full-year revenue and organic-growth outlook, forecasting organic growth of 6%–9%. Fiscal 2027 outlook
• Positive Sentiment: Analyst price targets rose: Citigroup raised its target to $149 and maintained a Buy rating; Barrington Research lifted its target to $145 with an Outperform rating; and BTIG raised its target to $142 with a Buy rating. Citigroup recommendations
• Neutral Sentiment: Growth comes with execution considerations: Haemonetics plans to scale the CSL Persona PLUS rollout through calendar 2027, and earnings-call coverage noted growth and margin tradeoffs. This may temper enthusiasm if rollout costs or margins disappoint. Earnings call highlights

Haemonetics Company Profile

Haemonetics Corporation (NYSE: HAE) is a healthcare technology company that develops and supplies products and services for blood and plasma collection, processing, and management. Its solutions are used by blood and plasma collection organizations, hospitals, and other healthcare providers to support the efficient handling of blood components and improve patient care.

The company’s offerings include automated plasma and blood-component collection systems, disposable collection sets, blood-processing equipment, and software designed to manage collection and transfusion-related operations.